$AME

AMETEK Stock: Is Wall Street Bullish or Bearish?

The article says 21 analysts cover AMETEK (AME) and the consensus is a “Moderate Buy,” with 13 “Strong Buy,” one “Moderate Buy,” and seven “Hold” ratings. It notes ratings have been stable over three months. TD Cowen reiterated a “Buy” on Aug. 6 and raised its price target to $275, implying 6.4% upside, while the street-high target is $316.

Original reporting
Published Aug 14, 2026, 10:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 10:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AMETEK Stock: Is Wall Street Bullish or Bearish? — source image
Decision brief

The 30-second read

$AMENeutralLow
01

Why it matters

For trading, the only actionable element is the incremental analyst target change, which may influence short-term sentiment but lacks new fundamental information.

02

Market read

Mildly bullish Street positioning (Moderate Buy) with a specific target raise, but no new earnings, guidance, or operational catalyst.

03

What to watch

The article does not discuss valuation, earnings revisions, or any changes in estimates, so traders may want to verify whether targets reflect real earnings upgrades.

Relevance 4/10Novelty 3/10Timing: after-hours/next-session positioning based on analyst-target narrative

Background

The article reports AME sell-side rating distribution and highlights a TD Cowen price-target increase to $275.

Company-level read

Ticker impact

$AMENeutralMedium confidence
Context

Article summarizes AME analyst consensus as “Moderate Buy” and notes TD Cowen raised its price target to $275, implying 6.4% upside.

Expected impact

Low incremental impact; any reaction would likely fade unless accompanied by new earnings or guidance.

Evidence & confidence

The newest concrete fact is a price-target raise by TD Cowen, but the article provides no new company-specific operational or financial disclosure.

Market effects

Minimal, since the piece is single-name analyst consensus and one target change without sector-wide new data.

Minimal, no regional macro or cross-market linkage described.

Minimal, no global demand, regulation, or supply-chain developments mentioned.

Counterpoint

Analyst consensus and price targets can lag fundamentals; without new earnings or guidance, the market may already price in the bullish narrative.

Key entities

  • AME

    AMETEK, Inc., the subject of the analyst-consensus and price-target discussion.

  • TD Cowen

    Brokerage cited as raising its AME price target to $275 while keeping a Buy rating.

Related articles

$AMEHighAI 9/10

AMETEK Completes Acquisition of Indicor Instrumentation

AMETEK, Inc. (NYSE: AME) completed its $5.0 billion acquisition of Indicor Instrumentation. The deal adds businesses that design and manufacture mission-critical industrial and scientific solutions. Indicor Instrumentation is expected to contribute $350 million to AMETEK's 2026 sales and be modestly accretive to earnings. The acquisition aligns with AMETEK's growth strategies and market focus.

$AMEHighAI 9/10

AMETEK Raises 2026 Outlook After Earnings Climb 17%

AMETEK (NYSE: AME) raised its 2026 outlook after Q2 results. Second-quarter adjusted earnings rose 17% to $2.09 per diluted share, with sales up 15% to $2.04 billion and orders up 28%. AMETEK now expects 2026 adjusted earnings of $8.20 to $8.30 per share and sales up about 10% from 2025.

$AMEHighAI 9/10

AMETEK (AME) Q2 2026 Earnings Call Transcript

AMETEK (AME) reported Q2 2026 net sales of $2.04B, up 15% year over year, with 10% organic growth. Adjusted EPS was $2.09, up 17%, above guidance of $1.96 to $2.00. Total orders were $2.3B, up 28%, backlog $4.11B. Full-year sales guidance rose about 10% and adjusted EPS to $8.20-$8.30.

$AMEMed

Segment Demand and Strategic Acquisitions Propel Growth

AMETEK (NYSE: AME) reported Q2 CY2026 revenue of $2.04 billion, up 15% year over year, beating Wall Street expectations. Non-GAAP EPS was $2.09, 4.8% above consensus. Management cited organic growth, rising orders and backlog of $4.11 billion, and contributions from acquisitions. Full-year guidance was raised, supported by AI, defense, and power grid demand.

$AMEMedAI 8/10

AMETEK, Inc. Q2 2026 Earnings Call Summary

AMETEK reported Q2 2026 momentum driven by multi-year infrastructure build-outs for AI, semiconductors, and power. Organic sales growth accelerated, with a record $4.11B backlog and about 80% expected to ship in 12 months. Core EMG margins rose 290 bps. Full-year 2026 organic sales guidance was raised to mid-to-high single digits; Indicor Instrumentation acquisition of $5B expected to close in H2 with 10% to 12% synergies.

$AMEHigh

AMETEK INC/ (AME): Results of Operations and Financial Condition

AMETEK INC/ (AME) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ametek8kexhibit99108042026.htm EX-99.1 Document Exhibit 99.1 AMETEK Announces Record Second Quarter 2026 Results and Raises Full Year Guidance Berwyn, Pa., Aug 4, 2026 – AMETEK, Inc. (NYSE: AME) today announced its financial results for the second quarter ended June 30,